Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022
February 22 2022 - 7:00AM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company, today announced that it
will host a live conference call and audio webcast on Monday,
February 28, 2022 at 4:30 p.m. ET to report financial results for
the fourth quarter and full-year ended December 31, 2021, and to
provide a business update.
To access the live conference call, please dial (833) 301-1150
(domestic) or (914) 987-7391 (international) at least five minutes
prior to the start time, and refer to conference ID 7171208. A live
audio webcast of the call and accompanying slide presentation will
be available in the Investors’ Events & Presentations section
of the Company's website, www.ateapharma.com. An archived webcast
will be available on the Atea website approximately two hours after
the event.
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical stage biopharmaceutical
company focused on discovering, developing and commercializing oral
therapies to address the unmet medical needs of patients with
life-threatening viral diseases. Leveraging the Company’s deep
understanding of antiviral drug development, nucleos(t)ide
chemistry, biology, biochemistry and virology, Atea has built a
proprietary nucleotide prodrug platform to develop novel product
candidates to treat single stranded ribonucleic acid, or ssRNA,
viruses, which are a prevalent cause of severe viral diseases.
Currently, Atea is focused on the development of orally-available,
potent, and selective nucleotide prodrugs for difficult-to-treat,
life-threatening viral infections, including severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that
causes COVID-19, hepatitis C virus (HCV), dengue virus and
respiratory syncytial virus (RSV). For more information, please
visit www.ateapharma.com.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Oct 2023 to Oct 2024